Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Argenx Se Stock Quote

Argenx Se (NASDAQ: ARGX)

$361.21
(-1.4%)
-$4.99
Price as of April 18, 2024, 1:10 p.m. ET

Argenx Se Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ARGX -2.54% +209.55% +25.34% +1,492%
S&P +20.88% +72.88% +11.56% +112%

Argenx Se Company Info

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.